Board of Directors
Usman “Oz” Azam, MD
Dr. Usman Azam was elected to the Tmunity board in 2018.
Most recently, Dr. Azam was the Head of the Cell & Gene Therapies Unit at Novartis Pharmaceuticals and was a member of the Pharmaceutical Executive Committee. He has an extensive US, Global and International pharmaceutical industry background, with strong experiences in science, clinical development, regulatory and commercial activities. While at Novartis, he lived and worked in the US and Switzerland. Previous roles at Novartis included Head of Global Medical Affairs & HEOR General Medicines, Chief Scientific Officer and Head of US Clinical Development & Medical Affairs and Global Head Regulatory Affairs for the Neurosciences & Ophthalmic Franchise.
Prior to Novartis, he was the Chief Executive Officer of Novaccel Therapeutics LLC, a company he founded focusing on accelerating assets in the translational medicine setting. Prior to this he served as Chief Medical Officer at Aspreva Pharmaceutics Inc, a company that focused on orphan and rare autoimmune disease states. Aspreva was acquired by Galenica SA in 2008. Prior to this he worked at Johnson & Johnson in Pharmaceutical Research & Development and in Medical Devices at Johnson & Johnson Ethicon. He started his life sciences career with Warner Lambert-Parke Davis in 1998. Dr. Azam is a member of the Executive Committee of the Alliance for Regenerative Medicine. Dr. Azam is a graduate of the University of Liverpool, United Kingdom, where he completed undergraduate studies in Human Biology & Anatomy. He graduated from the University of Liverpool School of Medicine and attained board certification as an Obstetrician & Gynecologist in the UK.
Jeffrey Leiden, M.D., Ph.D.
Dr. Jefferey Leiden, M.D., Ph.D. was elected as Non-Executive Chairman of the Board in January 2021.
Dr. Leiden is a physician and scientist who, for the last 40 years, has dedicated his career to improving the lives of people with serious diseases. His experience spans all aspects of the biotech and pharmaceutical industries. He is currently Executive Chairman of Vertex Pharmaceuticals, where he was previously Chief Executive Officer and President. During his tenure at Vertex, Dr. Leiden led the company as it discovered and developed four breakthrough medicines that treat the underlying cause of Cystic Fibrosis andthe first successful human gene editing treatment for patients with Sickle Cell Disease and β-Thalassemia. Before joining Vertex, Dr. Leiden was a Managing Director at Clarus Ventures, a life sciences venture capital firm. Before that, he served as President and Chief Operating Officer, and Chief Scientific Officer at Abbott Laboratories, where he had responsibility for running Abbott’s global pharmaceuticals business, including developing and launching Humira, the first fully human monoclonal antibody for the treatment of multiple autoimmune diseases. Dr. Leiden held several academic appointments before joining industry, including the Rawson Professor of Medicine and Pathology and Chief of Cardiology and Director of the Cardiovascular Research Institute at the University of Chicago, the Elkan R. Blout Professor of Biological Sciences at the Harvard School of Public Health, and Professor of Medicine at Harvard Medical School. He is an elected member of both the American Academy of Arts and Sciences and the Institute of Medicine of the National Academy of Sciences. Dr. Leiden currently serves as a director of Massachusetts Mutual Life Insurance Company, an insurance company and Chairman of the Board of Casana Healthcare, a private digital healthcare company. Dr. Leiden previously served as a director and the non-executive Vice Chairman of the board of Shire plc, a specialty biopharmaceutical company, and as a director of Quest Diagnostics, a medical diagnostics company. Dr. Leiden received his M.D., Ph.D., and B.A. degrees from the University of Chicago.
General Partner, Andreessen Horowitz
Jorge Conde was elected to the Tmunity board in 2019.
Mr. Conde is a General Partner at Andreessen Horowitz (a16z) where he leads investments at the cross section of biology, computer science and engineering. Prior to joining a16z, Mr. Conde served as Chief Strategy Officer for Syros (NASDAQ: SYRS), which is advancing a new wave of medicines that control expression of disease-driving genes to treat cancer and other diseases. He previously served as the company's Chief Financial Officer and Chief Product Officer, leading the platform strategy for Syros' novel gene regulation technology. Mr. Conde also cofounded Knome, a human genome interpretation company acquired by Tute Genomics in 2015. Earlier in his career, Mr. Conde worked in marketing and operations at MedImmune and as a biotechnology investment banker at Morgan Stanley. Mr. Conde holds an MBA from Harvard Business School, an MS from the Harvard-MIT Division of Health Sciences and Technology, and a BA in Biology from Johns Hopkins University. Mr. Conde was named one of the top 35 young innovators in the world by the MIT Technology Review and is a Henry Crown Fellow of the Aspen Institute and a member of the Aspen Global Leadership Network. He previously served on the board of the Museum of Science, Boston.
Board member, Audit Committee Chair, Dicerna Pharmaceuticals, Inc.
Patrick Gray was elected to the Tmunity board in 2019.
Mr. Gray is a board member and chair of the Audit Committee at Dicerna Pharmaceuticals, Inc., a Lexington, MA based biopharmaceutical company which is traded on NASDAQ. He brings extensive experience in accounting and financial reporting to our board of directors, having spent over 37 years with PricewaterhouseCoopers LLP (“PwC”) until his retirement in 2009. He is a Certified Public Accountant who spent 25 years as an Audit Partner serving clients ranging from Fortune 500 companies and multi-national companies to rapid-growth companies pursuing an initial public offering. At the time of his retirement, he served as the lead partner for the PwC U.S. firm Corporate Governance Group. Prior to that time, he held various other leadership positions with the firm, including leadership of the PW (Price Waterhouse) High Tech Group. He previously served on the boards of directors of Civitas, Solutions, Inc. and Datto, Inc. Mr. Gray has been selected to serve on our board of directors because of his extensive experience in accounting, auditing, financial reporting, deep understanding of financial controls and familiarity with growing public companies, experience in leadership positions at PwC and public company governance experience as leader of the PwC’s corporate governance group. Mr. Gray holds a BS in Economics from The Wharton School of the University of Pennsylvania.
Partner, Lilly Asia Ventures
Judith Li was elected to the Tmunity board in 2018.
Ms. Li is a Partner with Lilly Asia Ventures (LAV). Prior to joining LAV, she worked at McKinsey and Company’s New York office, focusing exclusively on pharmaceutical and medical devices, health insurance and healthcare provider engagements. She also worked at Partners Healthcare, Harvard University’s umbrella hospital network, where she focused on hospital administration, and co-founded a start-up focused on interventional nephrology. Ms. Li holds a Bachelor’s in biology from Harvard University and an MBA from Harvard University Business School.
Chair, Board of Directors, G1 Therapeutics
Garry Nicholson was elected to the Tmunity board in 2019.
Mr. Nicholson is Chair of G1 Therapeutics. Most recently, he served as President and Chief Executive Officer of XTuit Pharmaceuticals, where he also was a member of the board of directors. Prior to XTuit, Mr. Nicholson was President, Pfizer Oncology and was responsible for global commercialization and sales, clinical development and regulatory strategy, and business development. Prior to Pfizer, Mr. Nicholson also held various leadership positions in the oncology division of Eli Lilly and Company. He currently serves on the board of directors of G1 Therapeutics, Inc., Five Prime Therapeutics, Inc., SQZ Biotechnologies and Personal Genome Diagnostics. He was on the board of TESARO, Inc. which was acquired by GlaxoSmithKline in 2018. Mr. Nicholson holds an MBA from the University of South Carolina and earned his BS in Pharmacy at the University of North Carolina, Chapel Hill.
Founder and Chairman of the Parker Institute for Cancer Immunotherapy
Sean Parker was elected to the Tmunity board in 2018.
Mr. Parker is a philanthropist and entrepreneur with a record of launching genre-defining companies. He is the Founder and Chairman of the Parker Institute for Cancer Immunotherapy (PICI), the President of the Parker Foundation and Founder of the Economic Innovation Group. The Parker Institute for Cancer Immunotherapy was founded in 2016 and builds on Mr. Parker’s leadership in funding and promoting research into the relationship between the immune system and cancer. In the ensuing years, PICI has evolved into a leader in the immunotherapy field for cutting edge research collaboration and clinical development, including funding a landmark human trial using CRISPR technology. In addition to cancer research, Mr. Parker has led many initiatives that revolutionized the civic and social landscape. He was the co-founder of Napster at age 19 and of Plaxo at 21. In 2004 he partnered with Mark Zuckerberg to found Facebook and served as its first president.
Beth Seidenberg, MD
Founding Managing Director, Westlake Village BioPartners
Beth Seidenberg, MD was elected to the Tmunity board in 2018.
Dr. Seidenberg is a founding managing director of Westlake Village BioPartners and a general partner at Kleiner Perkins, a leading venture capital firm. A longtime life sciences investor, she has incubated-invested more than 20 biotech ventures. Dr. Seidenberg has a demonstrated ability to identify and accelerate medically meaningful molecules through development. Her expertise is grounded in her significant senior level industry experience with leadership roles at Amgen, Bristol-Myers Squibb and Merck Research Laboratories. Most recently, at Amgen, Dr. Seidenberg was chief medical officer and head of global development. Dr. Seidenberg holds a Bachelor of Science degree in biology and anthropology from Barnard College and attended medical school at the University of Miami School of Medicine. She completed her medical residency at Johns Hopkins University and the George Washington University, and Fellowship at the National Institutes of Health.
Partner, Ping An Ventures